Elvina Almuradova/LinkedIn
Mar 4, 2025, 11:18
Elvina Almuradova: ENHERTU Brings New Hope for Gastric Cancer
Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared a post on LinkedIn:
“Major Breakthrough: ENHERTU Brings New Hope for Gastric Cancer!
The Independent Data Monitoring Committee has recommended unblinding the DESTINY-Gastric04 trial due to the superior efficacy of ENHERTU!
- For the first time, a HER2-targeted therapy has shown a survival benefit in second-line metastatic gastric cancer.
- ENHERTU significantly prolonged overall survival compared to chemotherapy.
- The results will be shared with global regulatory authorities for full approval.
Gastric cancer has a poor prognosis, with a 5-year survival rate of only 5-10% in advanced stages. This breakthrough could change the treatment landscape for HER2+ gastric cancer!
Expect to hear a lot more about this in upcoming medical conferences—it’s likely to be one of the hottest topics!”
More posts featuring Elvina Almuradova.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 4, 2025, 11:18
Mar 4, 2025, 11:14
Mar 4, 2025, 11:13
Mar 4, 2025, 11:11
Mar 4, 2025, 10:58
Mar 4, 2025, 10:32
Mar 4, 2025, 10:23